Press Releases

SYRACUSE, NY, 21 February, 2017 - Monaghan Medical Corporation (MMC) today announced the publication of a study in Pulmonary Therapy showing treatment with the Aerobika® device can significantly reduce the recurrence of exacerbations of COPD in the crucial 30-day period following hospitalization or emergency room visits.1 The study also showed that per-patient cost of exacerbations was significantly lower in the group using the Aerobika® device.  This study provides the first real-world evidenc


SYRACUSE, NY, January 12, 2017 – Monaghan Medical Corporation (MMC) today announced that the findings of a study published in the most recent issue of Academic Radiology shows that patients with non-cystic fibrosis (CF) bronchiectasis responded favorably to airway maintenance therapy using the Aerobika® device. This latest study adds to the growing base of evidence that demonstrates Monaghan’s drug-free Aerobika® device is effective for lung health maintenance.